Suppr超能文献

克拉霉素或阿莫西林加用高剂量雷尼替丁治疗幽门螺杆菌阳性功能性消化不良

Clarithromycin or amoxycillin plus high-dose ranitidine in the treatment of Helicobacter pylori-positive functional dyspepsia.

作者信息

Schütze K, Hentschel E, Hirschl A M

机构信息

Medical Department I, Hanusch Hospital, Vienna, Austria.

出版信息

Eur J Gastroenterol Hepatol. 1996 Jan;8(1):41-6. doi: 10.1097/00042737-199601000-00008.

Abstract

OBJECTIVE

This study was intended to investigate the effect of ranitidine in dual anti-Helicobacter pylori therapy. Simultaneously, it was to evaluate the potential effect of H. pylori eradication on the symptomatology of H. pylori-positive dyspepsia.

PATIENTS AND METHODS

Fifty-four patients with H. pylori infection and symptoms of non-ulcer dyspepsia were randomly assigned to treatment with either amoxycillin 500 mg four times daily plus ranitidine 300 mg four times daily, clarithromycin 500 mg twice daily plus ranitidine 300 mg twice daily, clarithromycin 500 mg four times daily plus ranitidine 300 mg twice daily or clarithromycin 500 mg four times daily plus ranitidine 300 mg four times daily for a period of 12 days. In addition, ranitidine 150 mg twice daily was given for a further 16 days.

RESULTS

Eradication of H. pylori using the assigned treatments was achieved in 47% (seven out of 15), 50% (five out of 10), 70% (seven out of 10) and 77% (10 out of 13) of patients, respectively. Failure of therapy with clarithromycin was associated with primary or acquired resistance after treatment in 91% (10 out of 11). Symptom improvement was significant (P = 0.0001) and similar in all of the four treatment groups up to week 8. As regards H. pylori status, no differences in the mean symptom score improvement could be found between patients with eradication and those with persistent infection (12.3-7.0, P = 0.0001, n = 29 compared with 13.0-6.5, P = 0.004, n = 19). After 1 year the symptom score had increased both in patients with persistent H. pylori (9.1) and in those remaining free of infection (10.0). No reinfection could be found.

CONCLUSION

These results suggest that clarithromycin plus high-dose ranitidine is a combination which achieves reasonably high H. pylori eradication rates. However, treatment failure inevitably leads to clarithromycin resistance. The improvement of non-ulcer dyspepsia symptoms during acute therapy is independent of H. pylori eradication. Long-term benefit of H. pylori eradication with respect to the symptoms of functional dyspepsia was not observed.

摘要

目的

本研究旨在调查雷尼替丁在双重抗幽门螺杆菌治疗中的作用。同时,评估根除幽门螺杆菌对幽门螺杆菌阳性消化不良症状的潜在影响。

患者与方法

54例幽门螺杆菌感染且有非溃疡性消化不良症状的患者被随机分配接受以下治疗:阿莫西林500毫克每日4次加雷尼替丁300毫克每日4次;克拉霉素500毫克每日2次加雷尼替丁300毫克每日2次;克拉霉素500毫克每日4次加雷尼替丁300毫克每日2次;或克拉霉素500毫克每日4次加雷尼替丁300毫克每日4次,为期12天。此外,雷尼替丁150毫克每日2次再服用16天。

结果

采用指定治疗方案根除幽门螺杆菌的患者比例分别为47%(15例中的7例)、50%(10例中的5例)、70%(10例中的7例)和77%(13例中的10例)。克拉霉素治疗失败与治疗后原发性或获得性耐药相关,比例为91%(11例中的10例)。在第8周前,所有四个治疗组的症状改善均显著(P = 0.0001)且相似。就幽门螺杆菌状态而言,根除幽门螺杆菌的患者与持续感染的患者在平均症状评分改善方面无差异(12.3 - 7.0,P = 0.0001,n = 29,相比13.0 - 6.5,P = 0.004,n = 19)。1年后,持续感染幽门螺杆菌的患者(9.1)和仍未感染的患者(10.0)症状评分均有所增加。未发现再次感染。

结论

这些结果表明,克拉霉素加高剂量雷尼替丁联合使用可实现较高的幽门螺杆菌根除率。然而,治疗失败不可避免地导致克拉霉素耐药。急性治疗期间非溃疡性消化不良症状的改善与幽门螺杆菌根除无关。未观察到根除幽门螺杆菌对功能性消化不良症状的长期益处。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验